<DOC>
	<DOC>NCT02913313</DOC>
	<brief_summary>A study to evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 alone and in Combination with Nivolumab in Advanced (Solid Tumor) Cancers</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumor) Cancers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Women and men â‰¥18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Must have received and progressed on or failed one standard/approved treatment for cancer type, if available At least 4 weeks since any previous treatment for cancer Subject must consent to pretreatment and on treatment tumor biopsies At least one lesion with measurable disease at baseline Adequate organ and marrow function Patients with primary brain tumors or primary tumors with central nervous system metastases as only location of disease. Controlled brain metastases are permitted Prior organ transplant Participants with second/other active cancers requiring current treatment Uncontrolled/significant heart disease History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS) Active/uncontrolled autoimmune disease Active infection Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>